将RMC-4998与sotorasib结合使用,抑制了细胞增殖和下游信号转导,对KRAS突变肿瘤的疗效显著。 RMC-7977:靶向KRAS、NRAS和HRAS,在临床前研究中,RMC-7977导致KRAS突变肿瘤的退缩,并在KRAS外显子12改变的肿瘤模型中显示出显著的疗效。最近,RMC-7977已在KRAS突...
We also employed cell line models of established KRAS mutant NSCLC and determined therapeutic vulnerabilities through pharmacological inhibition. We analysed differences in survival outcomes for patients affected by advanced KRAS G12C or KRAS G12D -mutant NSCLC. Results KRASG12D exhibited higher potency...
9例KRAS突变低级别浆液性卵巢癌患者,其中6例G12D,2例G12V,1例G12A,总有效率56%,其中2例已经缓解维持2.5年以上。7例KRAS G12V突变非小细胞肺癌,VS-6766单药治疗4例,VS-6766联合Defactinib治疗2例,总有效率57%。 卵巢癌:VS-6766+Defactinib NSCLC:VS-...
Inhibition of KRAS(G12D) mutant cell lines The promising results for the inhibitory activity and mutant-selectivity from the ITC and KRAS–CRAF interaction assays motivated us to evaluate the potential anti-cancer effects of TH-Z827. The KRAS G12D mutation is the most prevalent mutation form ...
评估GFH375在携带KRAS G12D 突变的晚期实体瘤患者中的安全性/耐受性、PK 和初步有效性,并确定GFH375 的 MTD 和/或 RP2D。 评估GFH375 在携带KRAS G12D 突变的晚期实体瘤患者中的有效性。 开始日期2024-07-02 申办/合作机构 劲方医药科技(上海)有限公司初创企业 ...
在PDAC中,KRAS蛋白的12号氨基酸最常突变的位点,其中以KRASG12D突变类型最为常见,其次是KRSAG12V。目前针对KRAS突变靶点的药物甚少,主要的药物靶向策略是设计选择性共价抑制剂,其通过与激活状态的KRAS以及青环素A之间形成稳定的、高亲和力的复合物达到抑制效果,但这些药物都尚未使用等基因癌症模型进行验证,对PDAC患者的...
[2] Gray JE, Hsu H, Younan D, et al. Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond. Lung Cancer. 2023. 181: 107260. [3] Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in Non-S...
Wouter W等人分析比较了464例应用不同方案化疗对KRAS突变患者的影响[3],发现紫杉醇联合铂的客观缓解率(ORR)及PFS要优于应用培美曲塞联合铂类的治疗方案,在亚组分析中发现存在G12V突变患者,紫杉醇类药物显著改善了ORR(67%, P <0.01),但未观察到PFS和总生存(OS)的延长;然而存在G12C或G12D突变的患者在所有...
10.Gadgeel S,Rodríguez-Abreu D,Speranza G,et al.Updated Analysis From KEYNOTE-189:Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer[J].J Clin Oncol,2020:JCO1903136. ...
The KRAS G12D mutation is the most prevalent type of pancreatic cancer and is found in about 35% of patients. Numerous natural chemicals are frequently investigated in cancer treatment to decrease side effects. Resveratrol (RVT) is a polyphenol that can promote cancer cell apoptosis and improve ...